AstaZeneca says the European Medicines Agency has accepted a marketing authorisation application for its gout treatment lesinurad.

Lesinurad is a selective uric acid reabsorption inhibitor developed for the treatment hyperuricaemia in combination with the xanthine oxidase (XO) inhibitors allopurinol or Takeda's Uloric (febuxostat) in gout patients when additional therapy is warranted. The submission is based on data from three Phase III studies.

AstraZeneca noted that between 40%-80% of patients do not achieve recommended serum uric acid (sUA) goals with the current standard of care of an XO inhibitor alone. The firm says that combination therapy “provides a dual mechanism approach targeting both excretion and production of uric acid”.

The drugs major got hold of lesinurad through its $1.26 billion acquisition of Ardea Biosciences in June 2012.